Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD

MLA

Anne-Emmanuelle Berger, et al. “Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.” Digestive Diseases and Sciences, vol. 63, June 2018, pp. 2714–21. EBSCOhost, https://doi.org/10.1007/s10620-018-5144-y.

APA

Anne-Emmanuelle Berger, Yara Nasser, Xavier Roblin, Ines Harzallah, Stéphane Paul, & Remi Labetoulle. (2018). Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD. Digestive Diseases and Sciences, 63, 2714–2721. https://doi.org/10.1007/s10620-018-5144-y

Chicago

Anne-Emmanuelle Berger, Yara Nasser, Xavier Roblin, Ines Harzallah, Stéphane Paul, and Remi Labetoulle. 2018. “Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.” Digestive Diseases and Sciences 63 (June): 2714–21. doi:10.1007/s10620-018-5144-y.